Please select the option that best describes you:
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Do you weigh any specific clinical or disease factors?
Answer from: Medical Oncologist at Community Practice
I would select Dato-DXD for patients with EGFR-mutated NSCLC, after I have trialed osimertinib and amivantamab in the first- and second-line setting. I usually include chemotherapy with one of these two medications as well. If a patient fails both of these treatments, I would consider Dato-DXD at th...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
Dato-DXd is typically selected for patients with EGFR-mutated non-small cell lung cancer (NSCLC) after they have progressed on both prior EGFR-directed therapy (such as osimertinib) and platinum-based chemotherapy.
Factors to consider:
EGFR mutation status: Dato-DXd is effective for NSCLC with E...